PS-02-012 Oxytocin treatment of the female partner improves sexual function and depression in untreated men

Abstract

OXYTOCIN TREATMENT OF THE FEMALE PARTNER IMPROVES SEXUAL FUNCTION AND DEPRESSION IN UNTREATED MEN Sheikh Rezaei, S.; Muin, D.; Wolzt, M.; Luger, A.; Bayerle-Eder, M. Medical University of Vienna, Austria Objective: To assess sexual function and life quality in men whose female partners are under treatment for female sexual dysfunction with oxytocin. Methods: Open prospective cohort and questionnaire study on male partners of 30 pre-and postmenopausal women with female sexual dysfunction held at the Department of Clinical Pharmacology,Medical University of Vienna, Austria. Over 22 weeks, men were asked to fill in questionnaires at baseline and after 3 and 5 months, respectively, including Sexual Life Quality (SLQ), Sexual Activity Record (SAR), Partner Performance Questionnaire (PPQ) andHamilton Depression Scale (HDS). Medical and sexual history were obtained, a urological examination excluded erectile dysfunction, sexual abuse, psychiatric diseases, untreated sexual dysfunction and therapy with negative side effects on sexual function. Results: Body mass index was <23 kg/m2, mean blood pressure at the time of inclusion was <135/85. SLQ in men improved significantly from -7.4± 9.9 to 7.9± 11.6 under female partner’s oxytocin use and 11.4 ± 14.0 under placebo (p < 0.04). Frequency of intercourse improved from 6.3 ± 3.9 at baseline to 7.3±4.0 under female oxytocin therapy, but not under placebo. Male satisfaction with orgasmduring intercourse improved significantly frombaseline 8.0±1.6 to 9.0±1.2 under oxytocin (p<0.04) anddecreased to5.2 ± 3.5 under placebo (p < 0.04). Male desire and arousal remained stable under female treatment. Evaluation of female partner’s performance by men improved significantly from 8.9 ± 2.8 at baseline to 10.6 ± 2.2 under oxytocin and to 11.2 ± 2.6 under placebo, respectively (p < 0.04). HDS in men improved from 1.5 ± 1.7 at baseline to 1.2± 2.6 (p1⁄4 0.07) under oxytocin, however decreased significantly under placebo (p < 0.04), especially when given oxytocin prior to placebo in women. Conclusion: Treatment of sexual dysfunction in female patients improves sexual quality of life, subjective evaluation of female sexual performance and depression in their male partners. Policy of full disclosure: None.